NMN/NR Geriatric Dosing: Safe Nicotinamide Mononucleotide and Riboside Use After 65

Nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR, sold under brand names such as Niagen) are both NAD+ precursor compounds, not the same molecule, and not interchangeable in regulatory terms. NR is marketed as a dietary supplement. NMN's status as a lawfully marketable supplement in the United States has been disputed by the FDA since 2022 (see the regulatory section below). Neither compound is an FDA-approved drug for any indication, and neither has a geriatric-specific dosing label. Any dose discussed here reflects small, short human trials in adults who were not selected for age-related organ decline, plus extrapolation and site judgment. This is not label guidance.

This is a case where the honest answer is narrower than the marketing claims. No randomized trial has enrolled a dedicated cohort of adults 65 and older with typical geriatric comorbidities (reduced renal clearance, polypharmacy, frailty) to establish a safe or effective dose of NMN or NR. Available trials used doses in roughly the 250 mg to 2,000 mg per day range in younger or middle-aged adults over periods no longer than about 12 weeks, with no serious adverse events reported at those doses in those populations. For a patient over 65, that evidence supports a conservative starting dose and structured monitoring, not a validated therapeutic protocol.

Why the question is different after 65

NAD+ concentrations decline with age, and this is one of the more consistently reported findings in aging biology; observational human studies and animal work both describe this decline, though the exact magnitude reported varies by tissue, assay method, and study population. Lower NAD+ availability has been linked in preclinical models to reduced mitochondrial respiration, impaired PARP-dependent DNA repair, and reduced sirtuin activity. Whether restoring blood or tissue NAD+ with an oral precursor reverses any of these downstream effects in humans, particularly in adults over 65, has not been established.

Age also changes the pharmacology around the drug, independent of what NAD+ does. Glomerular filtration rate declines on average as people age, hepatic conjugation capacity can shift, and polypharmacy increases competition for shared metabolic pathways. These are reasons for caution in dose selection, not reasons to avoid supplementation outright.

What the trials actually tested, and what remains unverified

Several small trials have tested NMN or NR in adults, including some middle-aged and older participants. Reported themes across this early literature include: NMN doses in the range of roughly 250 mg per day were associated with improved measures of insulin sensitivity in a small trial of postmenopausal women with prediabetes; NR doses in the range of roughly 300 mg to 1,000 mg per day raised blood NAD+ metabolites in middle-aged and older adults over several weeks; and single or short-course dosing up to roughly 2,000 mg per day of NR in a small trial of adults with obesity was reported as well tolerated without serious adverse events.

This section lacks full citation details because we could not independently verify the referenced studies against primary sources during this revision. Prior to publication, an editor with access to the original literature should validate each NAD-NMN study's trial design, participant count, dosing regimen, treatment duration, and measured outcomes, then either add complete citations or maintain general language. Until this verification is completed, readers and practitioners should regard the figures presented here as preliminary estimates rather than established findings.

What is not in dispute: none of the published trials enrolled a cohort defined by age 65+, reduced renal function, or significant polypharmacy. Trial durations topped out at roughly 12 weeks. No trial has followed participants for months or years, so nothing is known about long-term safety in older adults from controlled human data.

A conservative starting-dose approach

In the absence of a geriatric label or guideline, a conservative approach mirrors general geriatric prescribing principles: start low, use the lowest dose associated with a measurable biological effect in the available trials, and titrate slowly with monitoring.

• NMN: a starting dose of 250 mg once daily, with a meal, is at the lower end of doses used in published trials. Titration to 500 mg per day might be considered after 4 to 6 weeks if tolerated and renal function is stable. Doses substantially above this have been tested in short trials in younger or middle-aged adults, but not with the safety monitoring a frail older adult would need.
• NR: a starting dose of 300 mg once daily is at the lower end of doses that have produced measurable blood NAD+ changes in published trials. Titration to 500 to 600 mg per day after 4 weeks is a reasonable, cautious step. Doses above 1,000 mg per day should be reserved for patients under closer monitoring, since long-term data in frail or multimorbid older adults do not exist.

These are starting points for a clinician-supervised trial, not individualized dosing instructions, and they do not substitute for a conversation with the patient's own prescriber about their specific kidney function, medication list, and goals.

Renal function: a real gap in the evidence

Kidney function declines with age on average, and NMN, NR, and their downstream metabolites (nicotinamide and its methylated conjugates) are cleared renally. No regulatory body or clinical guideline has published a dose-adjustment schedule for NMN or NR in renal impairment. That absence is a genuine gap, not an oversight in this article.

High-dose nicotinamide itself (the shared downstream metabolite of both NMN and NR) has been associated with hepatotoxicity and thrombocytopenia at gram-level doses used in some dermatology and oncology contexts. That is a different compound at a different dose than typical NMN/NR supplementation, but it is the closest human safety signal available for the shared metabolic pathway, and it argues for caution rather than reassurance in patients with reduced renal clearance.

A pragmatic, non-guideline-based approach:

• eGFR 60 or higher: standard conservative starting dose, routine labs.
• eGFR 30 to 59: same starting dose, but recheck renal function and liver enzymes at 4 weeks before any dose increase.
• eGFR below 30: avoid supplementation outside of nephrology co-management, given the absence of any dosing data in this group.

These thresholds are site judgment built from general geriatric renal-dosing caution, not a cited guideline specific to NMN or NR.

Drug interactions: mostly theoretical, still worth checking

Adults over 65 commonly take multiple prescription medications, and NAD precursors are not automatically inert additions to that regimen just because they are sold as supplements.

Hepatotoxic co-medications. Nicotinamide, the shared downstream metabolite, competes for hepatic methylation. Patients on methotrexate, high-dose statins, or valproate could reasonably have liver enzymes checked more often after starting an NAD precursor, though direct evidence of a clinically significant interaction in humans is lacking.

Anticoagulants. Nicotinamide has shown antiplatelet effects in animal studies. Whether this matters clinically at supplement doses in a patient on warfarin, apixaban, or rivaroxaban is unknown. Checking INR or the relevant anticoagulation marker a few weeks after starting is a low-burden precaution rather than a proven necessity.

Antidiabetic agents. If NMN meaningfully improves insulin sensitivity, as suggested by at least one small trial (see verification note above), a patient on metformin, a sulfonylurea, or insulin could theoretically see increased hypoglycemia risk. The likely magnitude at conservative doses is small, but tightening glucose monitoring for the first month is reasonable.

The most useful safety practice remains simple: patients should disclose all supplement use to their prescribers, and a pharmacist doing a geriatric medication review should see the full list, supplements included.

Homocysteine: a monitoring blind spot worth taking seriously

NAD precursor metabolism runs through nicotinamide N-methyltransferase, which consumes methyl groups from the body's SAMe pool. Mechanistically, chronic high-dose use could deplete methyl donors and raise homocysteine, a mechanism described in the methyl-balance literature rather than demonstrated specifically for NMN or NR in a long-term human trial.

Elevated homocysteine is an independent cardiovascular and cognitive risk factor, and older adults already tend to run higher baseline homocysteine due to age-related declines in B12 and folate status. Checking homocysteine at baseline and again at 8 to 12 weeks is a reasonable, low-cost monitoring step. If levels rise into a concerning range, addressing B12, folate, and B6 status before continuing the NAD precursor is a sensible, conservative response, though it is site judgment rather than a tested protocol specific to NMN or NR.

Route of administration: sublingual versus oral

NMN is sold in sublingual as well as oral capsule form. Some pharmacokinetic data suggest sublingual delivery can produce higher peak blood NAD+ metabolite levels shortly after dosing compared with an equivalent oral capsule, though whether that translates into any clinical benefit is unknown, and this specific comparison needs verification against the primary source before being stated as settled.

Practically, sublingual tablets require holding a tablet under the tongue for roughly a minute. Patients with dry mouth from anticholinergic medications, tricyclic antidepressants, or Sjögren syndrome may not absorb a sublingual dose reliably. Patients with swallowing difficulty may find sublingual dosing easier than capsules. NR has only been studied in oral capsule form in the published literature reviewed here.

Timing, duration, and stopping

NAD+ has a circadian pattern that peaks during waking hours, which is the mechanistic basis for the common recommendation to dose in the morning. No trial has directly compared morning versus evening dosing, and the recommendation rests on circadian biology plus scattered user reports of evening-dose insomnia rather than a controlled comparison.

No published trial of NMN or NR has run longer than about 12 weeks, so there is no trial-based evidence for how these compounds behave with months or years of continuous use in anyone, let alone in adults over 65. A time-limited trial with predefined checkpoints is a more defensible approach than open-ended, indefinite use.

Does adding NMN or NR fit a geriatric medication list?

Geriatric care generally favors deprescribing: removing medications and supplements that are not clearly earning their place in a patient's regimen. Adding an unregulated or contested-status supplement runs against that principle unless there is a clear, individualized reason and a plan to stop if it doesn't deliver.

Reasonable, measurable therapeutic targets for a trial of NMN or NR might include a documented blood NAD+ change, an improvement in HbA1c for a patient with prediabetes, or a validated functional measure such as a timed up-and-go test or a standardized quality-of-life instrument. If none of these show a meaningful change after roughly 12 weeks at an adequately titrated dose, stopping is a reasonable default rather than continuing indefinitely on the hope of a delayed benefit.

Professional bodies have generally described NAD+ repletion strategies as an area of ongoing research that requires larger, longer human trials before being incorporated into routine clinical guidance. That framing, rather than any specific quoted statement, is the safest way to characterize where the field currently stands; a direct quotation attributed to a specific society statement in an earlier version of this article could not be verified and has been removed pending confirmation of its source.

NMN's regulatory status is unsettled (verify before advising patients)

In late 2022, the FDA took the position that NMN could not be lawfully marketed as a new dietary ingredient because it had already been authorized for investigation as a new drug. That determination has been contested, and the practical enforcement picture (what is actually being sold and where) can shift. Anyone advising a patient on NMN should check the FDA's current dietary supplement ingredient guidance rather than relying on a static description, since this is a volatile, date-sensitive regulatory fact.

NR retains Generally Recognized As Safe (GRAS) status for supplement use, which is a more stable regulatory position than NMN's. For a patient concerned about long-term product availability, that is a relevant practical difference independent of any comparison of pharmacological effect.

Clinician discussion and monitoring framework

This framework is a structured way to have the conversation and track a trial of NMN or NR in a patient over 65. It is a site-built decision aid, not a clinical guideline, and it does not replace individualized judgment by the treating clinician.

What belongs to label guidance versus individualized care

Checkpoints and stop/escalate conditions

Conversation checklist for the clinician

• Confirm which compound (NMN or NR) and which brand or formulation the patient is using or considering, since regulatory status and evidence differ between them.
• Ask directly whether the patient has disclosed this to every prescriber; many older adults do not volunteer supplement use.
• Set one or two measurable success criteria before starting, not after.
• Agree on a stop date or stop condition at the outset, not only a start date.
• Document the discussion as a time-limited trial, not a permanent addition to the medication list.

Evidence boundary

Established: NAD+ levels decline with age in observational human data. NR has GRAS status for supplement sale; NMN's supplement marketability has been disputed by the FDA since 2022, a status that should be checked for the current date. Small, short trials in non-geriatric or partially-geriatric adult populations have reported that NMN and NR at doses in the low hundreds to low thousands of milligrams per day were generally well tolerated over periods up to about 12 weeks.

Plausible but unproven: That restoring blood NAD+ with these precursors produces clinically meaningful benefits (muscle function, glycemic control, cognition) specifically in adults over 65. That the interaction risks described above (hepatotoxic drugs, anticoagulants, antidiabetics) are clinically significant at typical supplement doses.

Not established: Any dose specific to adults 65 and older with reduced renal function. Any renal dose-adjustment schedule. Long-term (beyond about 12 weeks) safety or efficacy at any dose, in any age group. A causal link between chronic NMN/NR use and clinically significant homocysteine elevation in humans.

If a patient develops jaundice, unexplained bruising or bleeding, a significant unexplained decline in kidney function, or new neurological symptoms while taking NMN or NR, that warrants prompt medical evaluation rather than waiting for the next scheduled check.